The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Routine purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Liquid chromatography–mass spectrometry | Mass shift reveals modification or truncation |
| Typical purity specification | Greater than 95 percent | Reported as main-peak area percentage |
| Long-term storage | Minus 20 degrees Celsius or colder | Sealed, protected from light |
| Principal degradation routes | Oxidation, deamidation, aggregation | Monitored individually during stability studies |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
== Chemistry == Naloxone, also known as N-allylnoroxymorphone or as 17-allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one, is a synthetic morphinan derivative and was derived from oxymorphone (14-hydroxydihydromorphinone), an opioid analgesic. Oxymorphone, in turn, was derived from morphine, an opioid analgesic and naturally occurring constituent of the opium poppy. Naloxone is a racemic mixture of two enantiomers, (–)-naloxone (levonaloxone) and (+)-naloxone (dextronaloxone), only the former of which is active at opioid receptors. The drug is highly lipophilic, allowing it to rapidly penetrate the brain and to achieve a far greater brain to serum ratio than that of morphine. Opioid antagonists related to naloxone include cyprodime, nalmefene, nalodeine, naloxol, and naltrexone.
Starmer attends a UK–Ireland summit in Liverpool alongside Taoiseach Micheál Martin at which he says the two countries have "turned a page on the turbulent years" and are ready for a meaningful partnership. Conservative peer Lord Hamilton apologises after saying the Jewish community should "pay for their own" Holocaust memorial because they have "an awful lot of money" during a House of Lords debate on plans for a memorial near Parliament. 7 March – Reform UK suspends MP Rupert Lowe from the party and refers him to police, alleging he has made "threats of physical violence" against party chairman Zia Yusuf. Former Liverpool mayor Joe Anderson and city politician Derek Hatton are charged with bribery and misconduct relating to council contracts, along with 10 others. Former Secretary of State for Wales Simon Hart says that Mark Drakeford, the country's First Minister during the COVID-19 pandemic, "dented people's confidence" in the UK government by saying successful aspects of the fight against COVID were Welsh Government policy and the unsuccessful were UK government policy. 8 March – Former national security adviser Mark Sedwill tells the BBC's The Week at Westminster the potential deployment of UK troops to Ukraine could last "many years". 10 March – Mike Amesbury confirms he will stand down as the MP for Runcorn and Helsby following his conviction for assault, triggering a by-election. Home Secretary Yvette Cooper rejects calls from the family of David Amess for a public inquiry into his murder. Former Labour MP Thangam Debbonaire is introduced into the House of Lords.
=== Bleeding and blood clot risk === Cirrhosis can increase the risk of bleeding. The liver produces various proteins in the coagulation cascade (coagulation factors II, VII, IX, X, V, and VI). When damaged, the liver is impaired in its production of these proteins. This will ultimately increase bleeding as clotting factors are diminished. Clotting function is estimated by lab values, mainly platelet count, prothrombin time (PT), and international normalized ratio (INR). The American Gastroenterological Association (AGA) provided recommendations in 2021 in regards to coagulopathy management of cirrhotic patients in certain scenarios.
=== Availability === Progesterone is widely available in countries throughout the world in a variety of formulations. Progesterone in the form of oral capsules; vaginal capsules, tablets/inserts, and gels; and intramuscular oil have widespread availability. The following formulations/routes of progesterone have selective or more limited availability:
Sources: en.wikipedia.org
glutathione + a carboxylate This enzyme belongs to the family of hydrolases, specifically those acting on thioester bonds. The systematic name is S-acylglutathione hydrolase. It is also called citryl-glutathione thioesterhydrolase. Glutathione thiolesterase has also been found to catalyze the reaction
==== MeSH E05.300.510 – infusions, parenteral ==== MeSH E05.300.510.520 – infusions, intra-arterial MeSH E05.300.510.555 – infusions, intralesional MeSH E05.300.510.560 – infusions, intraosseous MeSH E05.300.510.590 – infusions, intravenous
The outer membrane of Gram-negative bacteria contains lipopolysaccharide, which acts as a barrier to vancomycin penetration. This barrier is why vancomycin is mainly used to treat infections caused by Gram-positive bacteria (except some nongonococcal species of Neisseria). The large hydrophilic molecule of vancomycin is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Under normal circumstances, this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents cell wall synthesis of the long polymers of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) that form the backbone strands of the bacterial cell wall, and prevents the backbone polymers from cross-linking with each other.
Sources: en.wikipedia.org
== Further reading == Wolf, Jeanne; Ali Larter, Always the Bad Girl; Parade; August 24, 2009; Retrieved July 24, 2010 Cavaco, Paul; Ali Larter: Her Allure Photo Shoot; Allure; Retrieved July 24, 2010 Our Heroine; Cosmopolitan; Retrieved July 24, 2010 Hiltbrand, David; Split personalities make solid role for Ali Larter; Chicago Tribune; January 31, 2007; Retrieved July 24, 2010 Longsdorf, Amy; 'Obsessed' star Ali Larter calls Allentown area a 'safe haven'; The Morning Call; April 26, 2009; Retrieved July 26, 2010 Passafuime, Rocco; Still Our Hottest Hero; The Cinema Source; September 18, 2010; Retrieved September 25, 2010
==== Balancing infection and autoimmunity ==== There is increasing evidence that certain genes selected during evolution offer a balance between susceptibility to infection and the capacity to avoid autoimmune diseases. For example, variants in the ERAP2 gene provide some resistance to infection even though they increase the risk of autoimmunity (positive selection). In contrast, variants in the TYK2 gene protect against autoimmune diseases but increase the risk of infection (negative selection). This suggests the benefits of infection resistance may outweigh the risks of autoimmune diseases, particularly given the historically high risk of infection. Several experimental methods such as the genome-wide association studies have been used to identify genetic risk variants that may be responsible for diseases such as type 1 diabetes and rheumatoid arthritis.
Calcium (20Ca) has 26 known isotopes, ranging from 35Ca to 60Ca. There are five stable isotopes (40Ca, 42Ca, 43Ca, 44Ca and 46Ca), plus one isotope (48Ca) with such a long half-life that it is for all practical purposes stable. Two isotopes of calcium, 40Ca and 48Ca, are doubly-magic, making them particularly stable nucliides. Calcium also has a cosmogenic isotope, 41Ca, with half-life 99,400 years. Unlike cosmogenic isotopes produced in the air, 41Ca is produced by neutron activation of solid 40Ca in rock and soil. Most of its production is in the upper meter of the soil column, where the cosmogenic neutron flux is still strong enough. Calcium-41 is also produced during stellar nucleosynthesis and decays to 41K, which can be used to understand formation and mixing between solar system reservoirs . The most stable artificial isotopes are 45Ca with half-life 162.61 days and 47Ca with half-life 4.536 days. All other artificial calcium isotopes have half-lives of minutes or less. 40Ca comprises about 97% of natural calcium and is mainly created by nucleosynthesis in stars (alpha process). Like 40Ar, however, some 40Ca is radiogenic, created by radioactive decay of 40K. While K–Ar dating has been used extensively in the geological sciences, the prevalence of 40Ca in nature initially impeded the proliferation of K-Ca dating in early studies, with only a handful of studies in the 20th century.
=== Hypersensitivity === Prior to the advent of the "human" lente insulins, the lente insulins (semi-lente, lente, and ultra-lente) were a combination of porcine and bovine insulin products that were filtered and combined with zinc to form the suspension. Even with product filtering, due to the animal origin, the human body might recognize the foreign protein as such and form antibodies against it. These reactions were slightly more likely with lente insulins than insulins derived from a solely porcine source, as bovine insulin was more immunogenic than porcine insulin.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.
Removing water slows hydrolysis and limits the mobility that drives aggregation. A dry powder is also less hospitable to microbial growth. These factors make cold storage of the solid form more forgiving than storage of a reconstituted solution.
Methionine oxidation, asparagine and glutamine deamidation, and non-covalent or covalent aggregation are the main routes reported for peptides of this class. Each is tracked as a separate impurity. Their relative abundance depends on formulation and storage history.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.